Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health

Peter Falkai, Nikolaos Koutsouleris, Katja Bertsch, Mirko Bialas, Elisabeth B. Binder, Markus Bühner, Alena Buyx, Na Cai, Silvia Cappello, Thomas Ehring, Jochen Gensichen, Johannes Hamann, Alkomiet Hasan, Peter Henningsen, Stefan Leucht, Karl Heinz Möhrmann, Elisabeth Nagelstutz, Frank Padberg, Annette Peters, Lea Pfäffel, Daniela Reich‐Erkelenz, Valentin Riedl, Daniel Rueckert, Andrea Schmitt, Gerd Schulte‐Körne, Elfriede Scheuring, Thomas G. Schulze, Rudolf Starzengruber, Susanne Stier, Fabian J. Theis, Juliane Winkelmann, Wolfgang Wurst, Josef PrillerFrontiers in Psychiatry 2022 · DOI

Abstract

The Federal Ministry of Education and Research (BMBF) established the German Center of Mental Health (DZPG) to foster a nationwide research network. The Munich/Augsburg consortium, known as PriMe (Precision in Mental Health), was selected as a core partner. PriMe focuses on "Understanding, predicting, and preventing chronicity" in schizophrenia (SZ), bipolar disorder (BPD), and major depressive disorder (MDD). By integrating interdisciplinary research across the lifespan—from at-risk stages to chronic illness—PriMe aims to implement a precision medicine framework that reduces the significant health burden and excess mortality associated with these disorders.

Introduction

Mental health disorders are among the leading causes of disability worldwide. In Germany, approximately one-third of adults meet the criteria for a mental illness annually. Despite current therapeutic options, up to 50% of patients experience "chronicity"—persistent symptoms that lead to social and vocational disability. Furthermore, individuals with severe mental illness face a reduced life expectancy of over 10 years, often due to preventable somatic comorbidities like cardiovascular disease.

PriMe addresses the current clinical gap caused by fragmented research. It proposes a "translational chain" that connects basic laboratory findings to individualized clinical predictions and real-world healthcare implementation.

The Lifespan Perspective and the Challenge of Chronicity

PriMe shifts the focus from merely treating acute episodes to intercepting the disease process at the "at-risk" and "first-episode" stages. This longitudinal perspective is critical because the trajectory of mental illness often involves a transition from unspecific affective symptoms to established episodic or chronic disorders.

Lifespan perspective on mental health: (A) Incidence and disease onset across age; (B) Prevalence and symptom overlap within the MDD, BD, and SZ spectrums; (C) Functional decline across disease stages from normal functioning to chronic disorders.

As shown in the figure above, the progression toward chronicity is marked by a significant decrease in functioning (Panel C). PriMe aims to identify the biological and behavioral markers that predict these transitions, allowing for earlier and more effective intervention.

The PriMe Translational Chain

The consortium organizes its research around four key stages:

  1. Multiscale Understanding: Utilizing "humanized" models, such as induced pluripotent stem cells (iPSCs) and animal models, to study the underlying mechanisms of disease.
  2. Individualized Prediction: Leveraging Machine Learning (ML) and the open-source NeuroMiner platform to identify "biotypes"—predictive markers that signal a high risk for a chronic course.
  3. Marker-Informed Trials: Moving toward stratified clinical trials where treatments (e.g., drug repurposing or neurostimulation) are matched to a patient’s specific biological profile.
  4. Real-World Implementation: Developing computer-aided decision support tools and "living guidelines" that update in real-time as new evidence emerges.

Infrastructure and Catchment Area

To ensure that precision medicine reaches patients beyond academic centers, PriMe has established a robust recruitment and dissemination network. This network bridges the gap between urban research hubs and rural healthcare providers.

The PriMe recruitment and dissemination network in Bavaria, centered in Munich and Augsburg, covering a catchment area of 6.2 million people and involving 32 teaching and community hospitals.

This infrastructure allows access to massive longitudinal datasets, including population cohorts like NAKO (n=20,500) and clinical cohorts like PRONIA (n=1,400). By integrating data from these diverse sources, PriMe can test the scalability and clinical utility of personalized treatments across a broad population.

Key Insights and Successes

PriMe members have already demonstrated the potential of this framework through several proof-of-concept successes:

  • Molecular Mechanisms: Identifying how childhood trauma interacts with the FKBP5 gene to increase the risk of stress-related diseases.
  • Drug Repurposing: Identifying Spironolactone, a common diuretic, as a potential treatment for cognitive deficits in schizophrenia.
  • Predictive Modeling: Showing that ML algorithms can predict poor functional outcomes in at-risk patients with higher accuracy than traditional clinical intuition.

Conclusion and Future Directions

The future of mental health care lies in the integration of somatic and psychiatric treatment. PriMe recognizes that conditions like Type II Diabetes and depression often share common immunological roots. By addressing these "common roots" and overcoming infrastructure hurdles—such as the lack of a unified digital backbone in the German healthcare system—PriMe aims to standardize precision medicine tools nationwide through the DZPG network. This shift from a "one-size-fits-all" approach to personalized prevention is essential to reducing the global burden of mental illness.

Summary updated

Abstract

The Federal Ministry of Education and Research (BMBF) issued a call for a new nationwide research network on mental disorders, the German Center of Mental Health (DZPG). The Munich/Augsburg consortium was selected to participate as one of six partner sites with its concept "Precision in Mental Health (PriMe): Understanding, predicting, and preventing chronicity." PriMe bundles interdisciplinary research from the Ludwig-Maximilians-University (LMU), Technical University of Munich (TUM), University of Augsburg (UniA), Helmholtz Center Munich (HMGU), and Max Planck Institute of Psychiatry (MPIP) and has a focus on schizophrenia (SZ), bipolar disorder (BPD), and major depressive disorder (MDD). PriMe takes a longitudinal perspective on these three disorders from the at-risk stage to the first-episode, relapsing, and chronic stages. These disorders pose a major health burden because in up to 50% of patients they cause untreatable residual symptoms, which lead to early social and vocational disability, comorbidities, and excess mortality. PriMe aims at reducing mortality on different levels, e.g., reducing death by psychiatric and somatic comorbidities, and will approach this goal by addressing interdisciplinary and cross-sector approaches across the lifespan. PriMe aims to add a precision medicine framework to the DZPG that will propel deeper understanding, more accurate prediction, and personalized prevention to prevent disease chronicity and mortality across mental illnesses. This framework is structured along the translational chain and will be used by PriMe to innovate the preventive and therapeutic management of SZ, BPD, and MDD from rural to urban areas and from patients in early disease stages to patients with long-term disease courses. Research will build on platforms that include one on model systems, one on the identification and validation of predictive markers, one on the development of novel multimodal treatments, one on the regulation and strengthening of the uptake and dissemination of personalized treatments, and finally one on testing of the clinical effectiveness, utility, and scalability of such personalized treatments. In accordance with the translational chain, PriMe's expertise includes the ability to integrate understanding of bio-behavioral processes based on innovative models, to translate this knowledge into clinical practice and to promote user participation in mental health research and care.
BibTeX
@inproceedings{falkai2022concept,
  author = {Peter Falkai and Nikolaos Koutsouleris and Katja Bertsch and Mirko Bialas and Elisabeth B. Binder and Markus Bühner and Alena Buyx and Na Cai and Silvia Cappello and Thomas Ehring and Jochen Gensichen and Johannes Hamann and Alkomiet Hasan and Peter Henningsen and Stefan Leucht and Karl Heinz Möhrmann and Elisabeth Nagelstutz and Frank Padberg and Annette Peters and Lea Pfäffel and Daniela Reich‐Erkelenz and Valentin Riedl and Daniel Rueckert and Andrea Schmitt and Gerd Schulte‐Körne and Elfriede Scheuring and Thomas G. Schulze and Rudolf Starzengruber and Susanne Stier and Fabian J. Theis and Juliane Winkelmann and Wolfgang Wurst and Josef Priller},
  title = {{Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health}},
  booktitle = {Frontiers in Psychiatry},
  year = {2022},
  doi = {10.3389/fpsyt.2022.815718},
}
Figure